Moby summary of Protalix BioTherapeutics, Inc.'s Q2 2026 earnings call

Revenue climbs 27% year-over-year, driven by higher Elfabrio sales to Chiesi, while the company advances its promising PRS-115 gout program.

The market has climbed 1.2% in the last 7 days and an impressive 29% over the past year, with earnings forecasted to grow by 17% annually. While penny stocks might seem like a relic from earlier market eras, they offer a unique opportunity for growth at lower price points, especially when backed by strong balance sheets and solid fundamentals. In this article, we explore several penny stocks that stand out as hidden gems with potential for impressive returns.

Moby summary of Protalix BioTherapeutics, Inc.'s Q1 2026 earnings call

Protalix BioTherapeutics Inc (PLX) reports a profitable quarter with significant milestone achievements and reaffirms its 2026 revenue guidance.

Protalix BioTherapeutics (AMEX:PLX) released first-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more. View the webcast at https://viavid.webcasts.com/starthere.jsp?ei=1762414&tp_key=330c698581 Summary Protalix BioTherapeutics reported a $25 million milestone payment from Chiesi due to European Commission a

The market has climbed 3.4% in the last 7 days and an impressive 30% over the past year, with earnings projected to grow annually by 16%. In light of these robust market conditions, identifying stocks with strong financials becomes crucial for investors looking to capitalize on growth opportunities. Although often considered a relic, penny stocks still hold potential when backed by solid fundamentals, offering a unique blend of value and growth that might not be found in larger companies.

Protalix BioTherapeutics Inc (PLX) reports significant EU approval, financial gains, and R&D progress amidst increased expenses and market challenges.

Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) reported its 2025 financial results and outlined recent regulatory, clinical and commercial developments, including a new European approval for its Fabry disease therapy and updated guidance for 2026. "2025 was a year of meaningful progress...

HACKENSACK, N.J. (AP) — Protalix BioTherapeutics Inc. PLX) on Wednesday reported a loss of $5.5 million in its fourth quarter. On a per-share basis, the Hackensack, New Jersey-based company said it had a loss of 7 cents.